Development of the Abl tyrosine kinase inhibitor (TKI) imatinib and other second-generation TKIs, dasatinib and nilotinib, has revolutionized the treatment of Ph+ leukemia, with remarkable rates of sustained complete cytogenetic remission and disease-free survival for CML patients at the chronic phase [6]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.